Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.45 |
| ▸ | JAK1 | P23458 | 8/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2789362 | 0.87 | JAK2 (0.58) | JAK2JAK1 | |
| SCHEMBL2787512 | 0.87 | JAK2 (0.58) | JAK2JAK1 | |
| SCHEMBL2787254 | 0.86 | JAK2 (0.51) | JAK2JAK1MAP3K5 | |
| SCHEMBL2786928 | 0.84 | JAK2 (0.56) | JAK2JAK1 | |
| SCHEMBL2771078 | 0.84 | JAK1 (0.57) | JAK2JAK1 | |
| SCHEMBL2786688 | 0.84 | JAK2 (0.50) | JAK2JAK1 | |
| SCHEMBL2788211 | 0.84 | MAP3K5 (0.60) | JAK2JAK1F10MAP3K5TYRO3 | |
| SCHEMBL2790696 | 0.82 | JAK2 (0.49) | JAK2JAK1 | |
| SCHEMBL2787694 | 0.81 | JAK1 (0.53) | JAK2JAK1MAP3K5 | |
| SCHEMBL2790848 | 0.81 | JAK1 (0.49) | JAK2JAK1MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-8263595-B2 | Triazolopyridine compounds and their use as ask inhibitors | MERCK SERONO SA (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MERCK SERONO SA (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-2181112-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | Merck Serono S.A. (CH) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MAP3K5, MAPKAPK5, MAP3K9 | JAK2 228/4885JAK1 229/4885F10 4705/4885 |
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MAP3K5, MAPKAPK5, MAP3K9 | JAK2 228/4885JAK1 229/4885F10 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.